Japan· JP-2121400A1018
プロカインアミド塩酸塩
A procainamide product containing プロカインアミド塩酸塩, registered in Japan, on the national reimbursement list. The same ATC class is registered in 5 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Procainamide is registered in 5 of 19 countries.
Countries holding a registration under ATC C01BA02 (procainamide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 2 of them publish a price we can compare per daily dose
Procainamide · ATC C01BA02
5 / 19 countries
- Canada
- Finlandprice
- Japan
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- プロカインアミド塩酸塩
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- C01BA02
- ATC class
- Procainamide
- Defined daily dose
- 3 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
236 interactions on record for procainamide.
Graded by severity as the source publishes them — 138 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Procainamide · interactions on record
236 records
- 138 severe
- 85 moderate
- 8 minor
- 4 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C01BA02
Procainamide, as other registers publish it.
- FinlandCardiorytminSchering Oy
- FinlandCardiorytminSchering Oy
- FinlandCardiorytmin RetardSchering Oy
- United KingdomProcainamide 250mg capsulesSpecial Order
- United StatesPROCAINAMIDE HCIHF Acquisition Co LLC, DBA HealthFirst
- United StatesProcainamide HydrochlorideHospira, Inc.
- United StatesProcainamide HydrochlorideCaplin Steriles Limited
- United StatesProcainamide HydrochlorideMedical Purchasing Solutions, LLC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e8d7f088-f0e9-4d5d-9b6c-ef36c4a5f102 GET /v1/drugs/e8d7f088-f0e9-4d5d-9b6c-ef36c4a5f102?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１０％１ｍＬ１管",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "2121400A1018",
"category": "注射薬",
"price_yen": null,
"generic_name": "プロカインアミド塩酸塩",
"product_name_jp": null,
"therapeutic_class": "2121",
"transitional_expiry": null
}See everything about procainamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.